Outcome of SARS-CoV-2 reinfection depends on genetic background in female mice
Open Access
- 23 November 2024
- journal article
- research article
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Abstract
Antigenically distinct SARS-CoV-2 variants increase the reinfection risk for vaccinated and previously exposed population due to antibody neutralization escape. COVID-19 severity depends on many variables, including host immune responses, which differ depending on genetic predisposition. To address this, we perform immune profiling of female mice with different genetic backgrounds –transgenic K18-hACE2 and wild-type 129S1– infected with the severe B.1.351, 30 days after exposure to the milder BA.1 or severe H1N1. Prior BA.1 infection protects against B.1.351-induced morbidity in K18-hACE2 but aggravates disease in 129S1. H1N1 protects against B.1.351-induced morbidity only in 129S1. Enhanced severity in B.1.351 re-infected 129S1 is characterized by an increase of IL-10, IL-1β, IL-18 and IFN-γ, while in K18-hACE2 the cytokine profile resembles naïve mice undergoing their first viral infection. Enhanced pathology during 129S1 reinfection cannot be attributed to weaker adaptive immune responses to BA.1. Infection with BA.1 causes long-term differential remodeling and transcriptional changes in the bronchioalveolar CD11c+ compartment. K18-hACE2 CD11c+ cells show a strong antiviral defense expression profile whereas 129S1 CD11c+ cells present a more pro-inflammatory response upon restimulation. In conclusion, BA.1 induces cross-reactive adaptive immune responses in K18-hACE2 and 129S1, but reinfection outcome correlates with differential CD11c+ cells responses in the alveolar space.Keywords
All Related Versions
This publication has 74 references indexed in Scilit:
- Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism1 1The authors thank Andrea Lippelman for editorial assistance; Drs. Fred Finkelman, Eric Brandt, Simon Hogan, and Paul Foster for helpful discussions and/or reagents; Drs. James and Nancy Lee (Mayo Clinic, Scottsdale, AZ) for the generous supply of anti-MBP; Dr. Debra Donaldson (Wyeth Research, Cambridge, MA) for the generous supply of recombinant IL-13; and Klaus Matthaei (Australian National University, Canberra, Australia) for the original supply of the IL-5 (Balb/c) gene targeted mice.Gastroenterology, 2003
- Allergen-induced airway disease is mouse strain dependentAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2003
- Transgenic Overexpression of Interleukin (IL)-10 in the Lung Causes Mucus Metaplasia, Tissue Inflammation, and Airway Remodeling via IL-13-dependent and -independent PathwaysJournal of Biological Chemistry, 2002
- Endotoxin-Induced Gamma Interferon Production: Contributing Cell Types and Key Regulatory FactorsClinical and Vaccine Immunology, 2002
- Treatment of Crohn's disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon γGut, 2002
- IL-13 and IFN-γ: Interactions in Lung InflammationThe Journal of Immunology, 2001
- Proinflammatory Effects of IL-10 During Human EndotoxemiaThe Journal of Immunology, 2000
- IL-10 deficiency prevents IL-5 overproduction and eosinophilic inflammation in a murine model of asthma-like reactionEuropean Journal of Immunology, 2000
- Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin productionJournal of Clinical Investigation, 1999
- Cytokine regulation by virus infection: bovine viral diarrhea virus, a flavivirus, downregulates production of tumor necrosis factor alpha in macrophages in vitroJournal of Virology, 1996